Abstract library

19 results for "Landoni".
#1165 Discrepancy Between Radiologic and Pathologic Measurements in Pancreatic Neuroendocrine Tumors: A Retrospective Study on 199 Patients
Introduction: Preoperative radiologic size of pancreatic neuroendocrine tumors (PNET) is a crucial parameter in selection of appropriate treatment especially for incidentally discovered lesions (<20 mm). The current guideline bases the therapeutic recommendations on the pathologic size.
Conference: 12th Annual ENETS Conference (2015)
Category: Surgical treatment
Presenting Author: MD Anna Malpaga
Keywords: size NET
#1174 Long-Term Follow-Up of Resected Small (< 2 Cm) Asymptomatic Sporadic Non-Functioning Pancreatic Neuroendocrine Tumors: Correlation Between Type of Resection, Histopathologic Features, and Outcome
Introduction: The surgical management of small, incidentally found sporadic non-functioning pancreatic neuroendocrine tumors (NF-PNET) is controversial
Conference: 12th Annual ENETS Conference (2015)
Category: Surgical treatment
Presenting Author: MD Anna Malpaga
Keywords: small
#1381 [18F]FDG-PET/CT as a Predictive Tool for Response to Chemotherapy and Everolimus Treatment in Patientes with Pancreatic Neuroendocrine Tumour
Introduction: The predictive role of 18F-FDG-PET/CT (FP) in neuroendocrine tumours is debated.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Silvia Ortolani
#1383 [18F]FDG-PET/CT Heterogeneity in Patients with Metastatic, Well-Differentiated Pancreatic Neuroendocrine Tumours
Introduction: 18F-FDG-PET/CT (FP) often shows an heterogeneous pattern of positivity in patients (P) with pancreatic neuroendocrine tumours (PanNETs).
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Silvia Ortolani
#1396 3-Drugs Chemotherapy Regimen for G3 PanNENs with Ki67 below 55%: Single Institution Experience
Introduction: To date no standard regimen of chemotherapy (CTH) is universally approved for advanced pancreatic neuroendocrine neoplasms (PanNENs) with Ki67<55% and no predictive selection criteria is available.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: MD Elisabetta Grego
#1422 Cystic Pancreatic Neuroendocrine Tumors: A Clinicopathologic Study and Long-term Follow-up after Surgical Resection in a Single Institution
Introduction: Cystic pancreatic endocrine tumors (CPETs) are rare lesions accounting for 2–17% of all endocrine pancreatic neoplasms. Their natural history and prognostic factors remain unclear
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: dr Anna Malpaga
Keywords: pancreas, cystic
#1424 Well Differentiated, Non Functioning Neuroendocrine Tumours of the Pancreas: A Surgical Series with Clinical and Pathological Correlations
Introduction: The only curative treatment for pancreatic neuroendocrine tumors (PNET) is surgery
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: dr Anna Malpaga
Keywords: grade
#1447 Clinicopathologic Features, Management and Outcome of Neuroendocrine Tumors (NETs) in MEN1: The Verona Multidisciplinary PlaNET Group
Introduction: Gastroenteropancreatic endocrine tumors (GEP-NETs) are a frequent manifestation of MEN1. They represent an important prognostic factor in these patients. There is still a debate on their management, mainly on surgical strategy, due to their multicentricity and high recurrence rate.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Elisa Cosaro
Keywords: MEN1, GEP-NET, management
#1722 New MEN-1 Gene Mutation Implicated in Familiar MEN-1 Syndrome Onset
Introduction: Multiple endocrine neoplasia type 1 (MEN1) is a rare genetic syndrome associated with an increased risk of developing parathyroid, pituitary and pancreatic neuroendocrine tumors. MEN1 has an autosomal dominant pattern of hereditability and it is usually related to mutations in menin coding gene
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: MD Elisabetta Grego
#1832 Are Cystic Pancreatic Neuroendocrine Tumors an Indolent Entity? Results for a Single Institutional Surgical Series
Introduction: Cystic pancreatic neuroendocrine tumors (CPanNET) are an uncommon variant of pancreatic neuroendocrine tumors (PanNETs). Due to their rarity, there is a lack of knowledge with regards to clinical features and prognosis.
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: MD Marco Miotto
Keywords: cystic
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.